Subscribe
shutterstock_1197730855_photobyphm
photobyphm / Shutterstock.com
29 July 2019Big PharmaRory O'Neill

Pfizer off-patent division to merge with Mylan

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.
Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.
Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.

More on this story

Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.
Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court